SynthesisPLoS neglected tropical diseases2021
The global burden of chromoblastomycosis.
Synthesis in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 99 citations in OpenAlex.
- Molecular Evidence of Autochthonous Environmental Acquisition ofOpen forum infectious diseases · 2026Article
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Article
- Predominance of Fonsecaea nubica in Chromoblastomycosis: A Single-Centre Study from Southern India.Mycopathologia · 2026Article
- Implantation mycoses: A nationwide survey on diagnostic and treatment modalities in Nepal.PLoS neglected tropical diseases · 2026Article
- Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.Microbiology (Reading, England) · 2026Article
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Chromoblastomycosis caused byIDCases · 2026Article
- Infrared Spectroscopy as a Promising Tool for Diagnosing and Typing Human Pathogenic Fungi.Mycoses · 2026Review
- Time-resolved multi-omics reveals macrophage-centered immunometabolic remodeling in cutaneous dematiaceous fungal infection.Frontiers in immunology · 2026Article
- Biological Activity of Silver(I)-1,10-Phenanthroline Complexes AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- An Atypical Case ofClinical medicine & research · 2025Article
- Widespread Verrucous Plaques of Chromoblastomycosis: A 12-Year Diagnostic Odyssey.Clinical case reports · 2025Article
- Concurrent chromoblastomycosis and eumycetoma: a unique case of dual neglected tropical fungal diseases in Asia.PLoS neglected tropical diseases · 2025Article
- Chromoblastomycosis in Peru: a retrospective review of 13 cases.BMC infectious diseases · 2025Article
- Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China.Tropical medicine and health · 2025Review
- Chromoblastomycosis: a case series from Sumba, eastern Indonesia.Clinical and experimental dermatology · 2025Article
- Dermatologic fungal neglected tropical diseases-Part I. Epidemiology and clinical features.Journal of the American Academy of Dermatology · 2025Review
- Establishment of epidemiological cutoff values forJournal of clinical microbiology · 2025Article
- Quality of Life, Disability, and Fungal Neglected Tropical Diseases.Current fungal infection reports · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination. METHODS AND
findingsIn order to estimate the global burden of CBM, we retrospectively reviewed the published literature from 1914 to 2020. Over the 106-year period, a total of 7,740 patients with CBM were identified on all continents except Antarctica. Most of the cases were reported from South America (2,619 cases), followed by Africa (1,875 cases), Central America and Mexico (1,628 cases), Asia (1,390 cases), Oceania (168 cases), Europe (35 cases), and USA and Canada (25 cases). We described 4,022 (81.7%) male and 896 (18.3%) female patients, with the median age of 52.5 years. The average time between the onset of the first lesion and CBM diagnosis was 9.2 years (range between 1 month to 50 years). The main sites involved were the lower limbs (56.7%), followed by the upper limbs (19.9%), head and neck (2.9%), and trunk (2.4%). Itching and pain were reported by 21.5% and 11%, respectively. Malignant transformation was described in 22 cases. A total of 3,817 fungal isolates were cultured, being 3,089 (80.9%) Fonsecaea spp., 552 (14.5%) Cladophialophora spp., and 56 Phialophora spp. (1.5%). CONCLUSIONS AND SIGNIFICANCE: This review represents our current knowledge on the burden of CBM world-wide. The global incidence remains unclear and local epidemiological studies are required to improve these data, especially in Africa, Asia, and Latin America. The recognition of CBM as NTD emphasizes the need for public health efforts to promote support for all local governments interested in developing specific policies and actions for preventing, diagnosing and assisting patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.